SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Alembic Pharmaceuticals’ Vadodara facility

10 Mar 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded an inspection at Alembic Pharmaceuticals’ Bioequivalence facility located at Vadodara. The inspection was conducted from March 03, 2025 to March 07, 2025. This was a scheduled inspection. The USFDA issued a form 483 with one procedural observation.

The Company will provide comprehensive response to USFDA for the observations within the stipulated period. The Company is committed to maintain the highest quality standards and compliance at all times. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

754.25 -4.75 (-0.63%)
21-Apr-2026 10:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.05
Dr. Reddys Lab 1223.90
Cipla 1230.70
Zydus Lifesciences 929.55
Lupin 2325.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×